Post-Hoc Analysis Completed

Systematic Review: Ketogenic Dietary Interventions for ADPKD

First comprehensive synthesis of all human keto-ADPKD studies confirms metabolic feasibility, calls for longer trials

Institution

University of Thessaly, Greece

Date

March 2026

Published In

Metabolism Open

Authors

Maria G. Grammatikopoulou, Arriana Gkouvi, Kalliopi K. Gkouskou, Dimitrios Poulimeneas, Christina Tsigalou, Theodoros Eleftheriadis, Odysseas Androutsos, Christos Cholevas, Ioannis Stefanidis, Maria Dalamaga, Dimitrios G. Goulis, Dimitrios P. Bogdanos

DOI

10.1016/j.metop.2026.100447

Study Design

Systematic review using the SWiM (Synthesis Without Meta-Analysis) approach. Searched three databases for human studies of ketogenic dietary interventions in ADPKD. Risk of bias assessed using Cochrane RoB 2.0, Newcastle-Ottawa scale, and ROBINS-I tool.

Intervention

Reviewed 8 studies employing ketogenic diets, intermittent fasting, and time-restricted feeding in ADPKD patients.

Key Results

+

Weight/Anthropometrics: Consistently improved

KDIs linked to weight loss and improved anthropometric profiles across 9 of the reviewed interventions.

+

Blood Pressure: Unchanged in most

Blood pressure remained stable in 5 interventions. Lipids (cholesterol, HDL, LDL, triglycerides) also unchanged — confirming safety.

+

eGFR: Improved or stable

eGFR was higher in 4 interventions or stable after intervention. No studies showed eGFR decline.

~

htTKV: Inconsistent

Evidence for renal structural change was inconsistent, limited by short intervention duration and small sample sizes.

Context & Comparison

This is the first formal systematic review of all ketogenic interventions in ADPKD, synthesizing evidence from KETO-ADPKD, RESET-PKD, Juntendo, Ren-Nu, TRE, and other studies.

Significance

The review confirms that ketogenic interventions are metabolically feasible and safe in ADPKD — no adverse effects on lipids, kidney function, or blood pressure. Current evidence supports metabolic feasibility more consistently than renal disease modification. The authors emphasize that longer trials with appropriate comparators are needed before KDIs can be formally recommended. Notably, the review was published before the Juntendo 12-month data (WCN 2026) which subsequently demonstrated significant TKV reduction.

systematic review meta-analysis Greece 2026 evidence synthesis safety confirmed

Disclaimer: This information is for educational purposes only and is not medical advice. Study information is based on publicly available data from published research and conference presentations. Consult your nephrologist before making treatment decisions.

Stay Updated on PKD Research

Get notified when new drugs enter clinical trials, trial results are published, or approved treatments change.

No spam. Unsubscribe anytime.